ID1 upregulation and FoxO3a downregulation by Epstein-Barr virus-encoded LMP1 in Hodgkin's lymphoma

Ikeda,Jun‑Ichiro; Wada,Naoki; Nojima,Satoshi; Tahara,Shinichiro; Tsuruta,Yoko; Oya,Kaori; Morii,Eiichi

doi:10.3892/mco.2016.1012

ID1 upregulation and FoxO3a downregulation by Epstein-Barr virus-encoded LMP1 in Hodgkin's lymphoma

Authors:
- Jun‑Ichiro Ikeda
- Naoki Wada
- Satoshi Nojima
- Shinichiro Tahara
- Yoko Tsuruta
- Kaori Oya
- Eiichi Morii
View Affiliations

Affiliations: Department of Pathology, Osaka University Graduate School of Medicine, Suita, Osaka 565‑0871, Japan
Published online on: September 8, 2016 https://doi.org/10.3892/mco.2016.1012
Pages: 562-566

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer-initiating cells (CICs) are specialized cells that have the ability to self‑renew and are multipotent. We recently demonstrated that Forkhead box O3a (FoxO3a)-expressing cells exhibited a CIC-like potential in Hodgkin's lymphoma (HL). A proportion of HL patients are infected with Epstein‑Barr virus (EBV). EBV‑encoded latent membrane protein (LMP) 1 downregulates FoxO3a, suggesting that FoxO3a expression may be abolished in EBV‑positive HL. Inhibitors of DNA‑binding (ID) proteins are highly conserved transcription factors mediating stem cell functions. To the best of our knowledge, no study has investigated possible associations among ID1, FoxO3a and LMP1 expression in HL to date. We immunohistochemically evaluated the expression of the three abovementioned factors in HL patients. The ID1 expression level was inversely correlated with that of FoxO3a (P=0.00035). LMP1‑positive HL cells abundantly expressed ID1 (P=0.029), but not FoxO3a (P=0.00085). Thus, our previous observation that FoxO3a may serve as a marker of CICs may not be applicable in EBV-positive HL patients, but rather ID1 may be a candidate CIC marker in this type of HL.

View Figures

View References

1	Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
2	Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
3	Ikeda J, Tian T, Wang Y, Hori Y, Honma K, Wada N and Morii E: Expression of FoxO3a in clinical cases of malignant lymphoma. Pathol Res Pract. 209:716–720. 2013. View Article : Google Scholar : PubMed/NCBI
4	Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, McNiece I, Lin L, Ambinder RF, Peacock C, et al: Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 68:190–197. 2008. View Article : Google Scholar : PubMed/NCBI
5	O'Brien CA, Pollett A, Gallinger S and Dick JE: A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. Nature. 445:106–110. 2007. View Article : Google Scholar : PubMed/NCBI
6	Rahadiani N, Ikeda J, Mamat S, Matsuzaki S, Ueda Y, Umehara R, Tian T, Wang Y, Enomoto T, Kimura T, et al: Expression of aldehyde dehydrogenase 1 (ALDH1) in endometrioid adenocarcinoma and its clinical implications. Cancer Sci. 102:903–908. 2011. View Article : Google Scholar : PubMed/NCBI
7	Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
8	Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C and De Maria R: Identification and expansion of human colon-cancer-initiating cells. Nature. 445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI
9	Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB: Identification of human brain tumour initiating cells. Nature. 432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
10	Sunayama J, Sato A, Matsuda K, Tachibana K, Watanabe E, Seino S, Suzuki K, Narita Y, Shibui S, Sakurada K, et al: FoxO3a functions as a key integrator of cellular signals that control glioblastoma stem-like cell differentiation and tumorigenicity. Stem Cells. 29:1327–1337. 2011.PubMed/NCBI
11	Touil Y, Zuliani T, Wolowczuk I, Kuranda K, Prochazkova J, Andrieux J, Le Roy H, Mortier L, Vandomme J, Jouy N, et al: The PI3K/AKT signaling pathway controls the quiescence of the low-Rhodamine123-retention cell compartment enriched for melanoma stem cell activity. Stem Cells. 31:641–651. 2013. View Article : Google Scholar : PubMed/NCBI
12	Yin S, Li J, Hu C, Chen X, Yao M, Yan M, Jiang G, Ge C, Xie H, Wan D, et al: CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer. 120:1444–1450. 2007. View Article : Google Scholar : PubMed/NCBI
13	Coffer PJ and Burgering BM: Stressed marrow: FoxOs stem tumour growth. Nat Cell Biol. 9:251–253. 2007. View Article : Google Scholar : PubMed/NCBI
14	Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, et al: Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 458:780–783. 2009. View Article : Google Scholar : PubMed/NCBI
15	Santamaría CM, Chillón MC, García-Sanz R, Pérez C, Caballero MD, Ramos F, de Coca AG, Alonso JM, Giraldo P, Bernal T, et al: High FoxO3a expression is associated with a poorer prognosis in AML with normal cytogenetics. Leuk Res. 33:1706–1709. 2009. View Article : Google Scholar : PubMed/NCBI
16	Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE, McDowell EP, Lazo-Kallanian S, Williams IR, Sears C, et al: FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell. 128:325–339. 2007. View Article : Google Scholar : PubMed/NCBI
17	Kanzler H, Küppers R, Hansmann ML and Rajewsky K: Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 184:1495–1505. 1996. View Article : Google Scholar : PubMed/NCBI
18	Marofioti T, Hummel M, Foss HD, Laumen H, Korbjuhn P, Anagnostopoulos I, Lammert H, Demel G, Theil J, Wirth T and Stein H: Hodgkin and reed-sternberg cells represent an expansion of single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood. 95:1443–1450. 2000.PubMed/NCBI
19	Jones RJ, Gocke CD, Kasamon YL, Miller CB, Perkins B, Barber JP, Vala MS, Gerber JM, Gellert LL, Siedner M, et al: Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood. 113:5920–5926. 2009. View Article : Google Scholar : PubMed/NCBI
20	Nakashima M, Ishii Y, Watanabe M, Togano T, Umezawa K, Higashihara M, Watanabe T and Horie R: The side population, as a precursor of Hodgkin and Reed-Sternberg cells and a target for nuclear factor-κB inhibitors in Hodgkin's lymphoma. Cancer Sci. 101:2490–2496. 2010. View Article : Google Scholar : PubMed/NCBI
21	Ikeda J, Mamat S, Tian T, Wang Y, Luo W, Rahadiani N, Aozasa K and Morii E: Reactive oxygen species and aldehyde dehydrogenase activity in Hodgkin lymphoma cells. Lab Invest. 92:606–614. 2012. View Article : Google Scholar : PubMed/NCBI
22	Ikeda J, Mamat S, Tian T, Wang Y, Rahadiani N, Aozasa K and Morii E: Tumorigenic potential of mononucleated small cells of Hodgkin lymphoma cell lines. Am J Pathol. 177:3081–3088. 2010. View Article : Google Scholar : PubMed/NCBI
23	Lasorella A, Benezra R and Iavarone A: The ID proteins: Master regulators of cancer stem cells and tumour aggressiveness. Nat Rev Cancer. 14:77–91. 2014. View Article : Google Scholar : PubMed/NCBI
24	Birkenkamp KU, Essafi A, van der Vos KE, da Costa M, Hui RC, Holstege F, Koenderman L, Lam EW and Coffer PJ: FoxO3a induces differentiation of Bcr-Abl-transformed cells through transcriptional down-regulation of Id1. J Biol Chem. 282:2211–2220. 2007. View Article : Google Scholar : PubMed/NCBI
25	Hau PM, Tsang CM, Yip YL, Huen MS and Tsao SW: Id1 interacts and stabilizes the Epstein-Barr virus latent membrane protein 1 (LMP1) in nasopharyngeal epithelial cells. PLoS One. 6:e211762011. View Article : Google Scholar : PubMed/NCBI
26	Li HM, Zhuang ZH, Wang Q, Pang JC, Wang XH, Wong HL, Feng HC, Jin DY, Ling MT, Wong YC, et al: Epstein-Barr virus latent membrane protein 1 (LMP1) upregulates Id1 expression in nasopharyngeal epithelial cells. Oncogene. 23:4488–4494. 2004. View Article : Google Scholar : PubMed/NCBI
27	Lo AK, Dawson CW, Lo KW, Yu Y and Young LS: Upregulation of Id1 by Epstein-Barr virus-encoded LMP1 confers resistance to TGFbeta-mediated growth inhibition. Mol Cancer. 9:1552010. View Article : Google Scholar : PubMed/NCBI
28	Gupta GP, Perk J, Acharyya S, de Candia P, Mittal V, Todorova-Manova K, Gerald WL, Brogi E, Benezra R and Massagué J: ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci USA. 104:19506–19511. 2007. View Article : Google Scholar : PubMed/NCBI
29	Wada N, Ikeda J, Hori Y, Fujita S, Ogawa H, Soma T, Sugiyama H, Fukuhara S, Kanamaru A, Hino M, et al: Epstein-barr virus in diffuse large B-cell lymphoma in immunocompetent patients in Japan is as low as in Western Countries. J Med Virol. 83:317–321. 2011. View Article : Google Scholar : PubMed/NCBI
30	Hummel M, Anagnostopoulos I, Dallenbach F, Korbjuhn P, Dimmler C and Stein H: EBV infection patterns in Hodgkin's disease and normal lymphoid tissue: Expression and cellular localization of EBV gene products. Br J Haematol. 82:689–694. 1992. View Article : Google Scholar : PubMed/NCBI
31	O'Brien CA, Kreso A, Ryan P, Hermans KG, Gibson L, Wang Y, Tsatsanis A, Gallinger S and Dick JE: ID1 and ID3 regulate the self-renewal capacity of human colon cancer-initiating cells through p21. Cancer Cell. 21:777–792. 2012. View Article : Google Scholar : PubMed/NCBI
32	Sun W, Guo MM, Han P, Lin JZ, Liang FY, Tan GM, Li HB, Zeng M and Huang XM: Id-1 and the p65 subunit of NF-κB promote migration of nasopharyngeal carcinoma cells and are correlated with poor prognosis. Carcinogenesis. 33:810–817. 2012. View Article : Google Scholar : PubMed/NCBI
33	Mathas S, Janz M, Hummel F, Hummel M, Wollert-Wulf B, Lusatis S, Anagnostopoulos I, Lietz A, Sigvardsson M, Jundt F, et al: Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol. 7:207–215. 2006. View Article : Google Scholar : PubMed/NCBI
34	Renné C, Martin-Subero JI, Eickernjäger M, Hansmann ML, Küppers R, Siebert R and Bräuninger A: Aberrant expression of ID2, a suppressor of B-cell-specific gene expression, in Hodgkin's lymphoma. Am J Pathol. 169:655–664. 2006. View Article : Google Scholar : PubMed/NCBI
35	Medina DJ, Abass-Shereef J, Walton K, Goodell L, Aviv H, Strair RK and Budak-Alpdogan T: Cobblestone-area forming cells derived from patients with mantle cell lymphoma are enriched for CD133⁺ tumor-initiating cells. PLoS One. 9:e910422014. View Article : Google Scholar : PubMed/NCBI
36	Ling MT, Wang X, Ouyang XS, Xu K, Tsao SW and Wong YC: Id-1 expression promotes cell survival through activation of NF-kappaB signalling pathway in prostate cancer cells. Oncogene. 22:4498–4508. 2003. View Article : Google Scholar : PubMed/NCBI
37	Hinz M, Lemke P, Anagnostopoulos I, Hacker C, Krappmann D, Mathas S, Dörken B, Zenke M, Stein H and Scheidereit C: Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med. 196:605–617. 2002. View Article : Google Scholar : PubMed/NCBI
38	Hinz M, Löser P, Mathas S, Krappmann D, Dörken B and Scheidereit C: Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood. 97:2798–2807. 2001. View Article : Google Scholar : PubMed/NCBI
39	Küppers R: The biology of Hodgkin's lymphoma. Nat Rev Cancer. 9:15–27. 2009. View Article : Google Scholar : PubMed/NCBI